Glass half-full? Embattled AstraZeneca CEO Soriot defends COVID-19 vaccine

As the weeks turn to months on AstraZeneca’s COVID-19 vaccine filing in the U.S., the big question is when. Its answer remains the same: soon.

But the next biggest question is, why bother?

With U.S. vaccine coffers now overflowing with Pfizer, Moderna and Johnson & Johnson shots, why is AstraZeneca still planning to file for emergency authorization here?